Your search for esrd returned 132 results

Your search for esrd returned 132 results

Sort Results:

Relevant Recent

Drugs in the Pipeline

Novel Anticoagulant Therapy for Patients With ESRD Gets Fast Track Status

Publish Date August 23, 2022

MK-2060 is an investigational monoclonal antibody designed to inhibit the activation of Factor XI and its ability to activate downstream proteins.

News

Diuretic Use Varies Widely in US Hemodialysis Practice

Publish Date August 16, 2022

Uncertainty regarding diuretic efficacy and optimal dosing in hemodialysis likely contributes to practice variation, according to investigators.

Clinical Charts

Antiretroviral Contraindications and Drug Interactions

Publish Date July 7, 2022

A list of contraindications and drug interactions for HIV medications.

News

Uric Acid-Lowering Therapy May Increase Risk for CKD

Publish Date June 22, 2022

Study findings do not support initiation of uric acid-lowering therapy to prevent CKD.

News

Preferential Use of Lactated Ringer vs Saline May Reduce Adverse Kidney Events

Publish Date May 11, 2022

This study raises important questions about the choice between lactated Ringer and saline.

News

Underuse of Diabetic Kidney Disease Therapies Reported

Publish Date April 29, 2022

Study findings highlight an "unmet need" for newer therapies.

News

Erectile Dysfunction Meds Tied to Higher Risk for Vision Issues

Publish Date April 12, 2022

Regular users may be at risk for serous retinal detachment, retinal vascular occlusion, and ischemic optic neuropathy

News

SGLT2 Inhibitors Underprescribed for Chronic Kidney Disease

Publish Date February 1, 2022

Affordability of SGLT2i may contribute to the low prescription rate in CKD.

SABCS 2021

Monitoring ESR1 Mutations May Optimize Treatment in Metastatic Breast Cancer

Publish Date December 13, 2021

Monitoring bESR1mut enabled optimization of the endocrine therapy used with a CDK4/6 inhibitor.

SABCS 2021

Elacestrant Improved PFS in Metastatic Breast Cancer Progressing on CDK4/6 Therapy

Publish Date December 9, 2021

Elacestrant showed a statistically significant and clinically meaningful progression-free survival improvement compared with standard of care.